nderstanding how increasing some of the brain's chemicals can help thinking and behaviour in people with Parkinson’s disease

Not Applicable

Completed

• Conditions: Parkinson's disease; Nervous System Diseases

• Registration Number: ISRCTN46299660
• Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-04-15
• Study Start: 2020-09-03
• Last Update Posted: 14 September 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

1. Idiopathic Parkinson’s disease
2. Hoehn and Yahr stage 1.5–3
3. Age 45 - 80 years
4. English speaking

Exclusion Criteria

1. Dementia (MMSE 25 or less)
2. Clinically significant current depression
3. Contraindications to MRI
4. Contraindication to atomoxetine, including:
4.1 Ischemic heart disease or cardiac rhythm abnormalities
4.2 other significant non-ischemic cardiac disease
4.3 uncontrolled hypertension
4.4 adverse drug reactions to closely related drugs
4.5 major psychiatric disorders including mania or schizophrenia
4.6 epilepsy
4.7 warfarin/monoamine oxidase inhibitor
4.8 known hepatic or renal failure

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Measured 2 hours after taking drug/placebo:<br> 1. Response inhibition measured using a stop-signal task and operationalised by the stop-signal reaction time (SSRT)<br> 2. Learning performance measured using a computerised reinforcement learning task<br> 3. Effort-based motivation measured using a computerised force production task<br> 4. Physiological measures measured using a 3-channel electrocardiogram (ECG) to measure heart rate, and an eye tracker to measure oculomotor function and pupil diameter<br>